Robot system good but not good enough

The da Vinci Surgical System (Intuitive Surgical) provides adequate dexterity for performing delicate intraocular manipulation, however, the kinematics of the robotic arms is insufficient for standard intraocular surgery.

The da Vinci Surgical System (Intuitive Surgical) provides adequate dexterity for performing delicate intraocular manipulation, however, the kinematics of the robotic arms is insufficient for standard intraocular surgery, according to a study published in the January issue of Retina.

Dan Bourla and colleagues from the Jules Stein Eye Institute, University of California, Los Angeles, USA assessed the feasibility of performing intraocular robotic surgery with the da Vinci Surgical System. Using the modified robotic instrument, 25-gauge pars plana vitrectomy, intraocular foreign body removal and anterior capsulorhexis were performed on porcine eyes.

Control of the wrist-like movements allowed for a full range of movement and the dexterity of the robotic arms was excellent, with steady instrument motion. However, controlling the robotic arms was not as intuitive as moving the wrist. A high stable point of rotation induced motion-related stress at the site of instrument insertion. Visualization of the external operative field during intraocular procedures did require camera realignment and absent retro-illumination made anterior segment surgery difficult to perform.

According to the study, the da Vinci Surgical System is promising but it requires a few adjustments in order to make it suitable for performing intraocular surgery.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.